- Spark Newswire

3 minute read

National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000

Today, 7:30 AM

The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.

ATAI

2 minute read

New York’s Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry

By David E. Carpenter

Today, 7:30 AM

Venture capitalist and businessman Stephen Jurvetson is joining an expanding group of prominent investors who are backing research into psychedelic ventures.

ATAI

2 minute read

Novamind Opens Addiction Clinic In Utah, Establishing Substance Use Disorder Program

By David E. Carpenter

Today, 7:30 AM

Novamind Inc. (OTCQB: NVMDF), a mental health company specializing in psychedelic medicine, has announced the launch of a new clinic located in downtown Salt Lake City specializing in integrative behavioral health and services for adults with substance use disorders.

NVMDF

3 minute read

Psychedelic Medicine: 5-MeO-DMT Formula For Treatment-Resistant Depression Has Positive Trial Results

By David E. Carpenter

Today, 7:30 AM

Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ: GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients suffering from treatment-resistant depression (TRD).

GHRS

2 minute read

New York City Conference ‘Horizons: Perspectives on Psychedelics’ A Who’s Who Of Notable Speakers

By David E. Carpenter

Today, 7:30 AM

In a welcomed throwback to the days before psychedelic use and research was considered a forbidden topic, the conference “Horizons: Perspectives On Psychedelics” in New York City is an incredible testimony to where the field of psychedelic therapy, and the industry as a whole, is

CMPS

2 minute read

Novamind Partners With Bienstar Wellness, Opening Door To Ibogaine Treatment For Addiction Disorders

By David E. Carpenter

Today, 7:30 AM

Novamind Inc. (OTCQB: NVMDF) a mental health company specializing in psychedelic medicine, recently announced a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company, to assist in the expansion of Latin Ameri

NVMDF

2 minute read

COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction

By David E. Carpenter

Today, 7:30 AM

As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared to 1mg and 10mg) occasioned an increase in positive feelings of in

CMPS

3 minute read

Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model

By David E. Carpenter

Today, 7:30 AM

Cybin (NYSE: CYBN), a biotech company focused on progressing psychedelic therapeutics, has announced that the FDA has given them authorization for Phase 2 clinical trials evaluating psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress

CYBN